Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SLN vs EVMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 2–5 Matrix Metrics)

EVMN Overall Winner 6-Pillar Tally: SLN 1 – 3 EVMN (2 Tie) Matrix Metrics: SLN 5 – 2 EVMN

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SLN carries a Unified Composite Score of 46.9/100 (HOLD) at $19.80 (N/M Forward P/E, -10475.6% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While SLN currently prints a higher short-term Unified Composite Score (46.9/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (2–5 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10475.6% operating margin) and revenue trajectory (+0.0% vs. +197.2% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLN vs EVMN
SLN NASDAQ
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.80
-0.15% 1D
Market Cap $1.2B
TTM Revenue $615,000
Forward P/E N/M
Beta / 30D Vol 1.91β · 4% Vol
Unified Composite Score
46.9 / 100 HOLD
Tech 24.0 Fund 34.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (18.5% over 20 days), RSI 77
RSI-14: 77.3 · SMA20: $19.75 · SMA50: $14.77
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47

6-Pillar Scorecard Institutional Category Breakdown (SLN 1 – 3 EVMN)

Columns: Metric · SLN · EVMN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SLN
Revenue Growth (YoY) +197.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $615,000 N/A
Market Cap $1.2B $315.5M
3. Profitability & Quality EVMN
Gross Margin 85.9% N/A
Operating Margin -10475.6% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -90.4% -69.5%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$64M EBITDA -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.32 Book/Sh · -90.4% ROE $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 55.4% (50th %ile) 209.0% (53rd %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLN (5) vs EVMN (2)
Institutional Metric SLN EVMN Criterion Row Edge
Market Capitalization
Scale
$1.2B $315.5M Larger Scale SLN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+197.2% +0.0% Higher Growth SLN
Operating Margin (TTM)
Profitability
-10475.6% 0.0% Higher Margin EVMN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-90.4% -69.5% Higher ROE EVMN
52-Week Range Position
Momentum
100% ($4–$20) 8% ($5–$33) Stronger Trend SLN
Beta / 30D Volatility
Risk Regime
1.91β · 4% Vol 1.05β · 118% Vol Lower Realized Risk SLN
Unified Institutional Score
Composite Signal
46.9 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite SLN
Trailing 12M Revenue (USD)
Operating Scale
$615,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
85.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M EBITDA ($1.32 Book/Sh · -90.4% ROE) -$75M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLN +90.78 pp
SLN: +128.11% · EVMN: +37.33%
3M Horizon SLN +90.5 pp
SLN: +40.43% · EVMN: -50.07%
6M Horizon SLN +285.39 pp
SLN: +217.82% · EVMN: -67.57%
1Y Horizon SLN +247.16 pp
SLN: +186.13% · EVMN: -61.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLN vs EVMN. Trailing 12-month operating profitability (SLN -10475.6% vs EVMN 0.0%) and valuation multiples (SLN N/M vs EVMN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SLN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$615,000
Gross Margin85.9%
Op. Margin-10475.6%
ROE / Fwd P/E-90.4% · N/M
EVMN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.4%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -10475.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SLN vs EVMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SLN carries a Unified Composite Score of 46.9/100 (HOLD) at $19.80 (N/M Forward P/E, -10475.6% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SLN currently prints a higher short-term Unified Composite Score (46.9/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (2–5 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10475.6% operating margin) and revenue trajectory (+0.0% vs. +197.2% YoY).

SLN leads the Growth & Scale pillar: SLN posts +197.2% YoY revenue growth and +0.0% YoY earnings growth on $615,000 TTM revenue (85.9% gross margin, -10475.6% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SLN generates $615,000 in USD-normalized revenue versus N/A for EVMN. In operating R&D and SG&A reinvestment, SLN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.

SLN and EVMN trade at balanced relative valuation multiples. SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLN (-90.4% ROE) versus EVMN (-69.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.91β · 4% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.